Truveta, a data platform company backed by some of the country’s largest health systems, is partnering with big pharma company Pfizer to monitor the safety of its COVID-19 vaccines and therapies.
Altogether, the partnership will give Pfizer access to data from Truveta's 20 health system members across 42 states. These health systems represent more than 16% of U.S. patient care.
Truveta said the partnership will allow Pfizer to evaluate and identify trends and treatments in real-time using de-identified data from 50 million people. The data doesn't just use clinical information from the electronic health record but socio-economic data and daily mortality data as well. The company's CEO Terry Myerson said he’s optimistic this deal can bolster trust and begin to combat vaccine hesitancy.
“I think at some level, that's why it's so important for us to have such a large data set, because even America is so diverse,” Myerson said. “I think that's a high bar for us to hit and we aspire to hit it. We aspire to be that trusted data set in the US that's representative.”
Myerson declined to share specifics on how health systems are compensated through this deal, but said it is relatively proportional to the overall number of patients. The company compensates its partners for anonymized patient data submitted by providers.
In November 2021, Truveta secured nearly $200 million in funding and launched its de-identified health data platform. It also added Ochsner Health, Saint Luke’s Health System and UnityPoint Health as members.
